No Data
No Data
Sinqi Pharmaceutical (300573): The operation is in line with expectations, and atropine will soon drive the company's rapid growth
Incident: The company released its 2023 annual report, achieving operating income of 1,468 billion yuan, a year-on-year increase of 17.4%; net profit to mother of 240 million yuan, an increase of 13.4%; deducted non-net profit of 240 million yuan, an increase of 15 percent year-on-year.
Sinqi Pharmaceutical (300573): Performance is in line with expectations, and the major single product atropine is about to be approved for release
The company released its 2023 annual report. For the whole year, the company achieved revenue of 1.47 billion yuan, +17.4% year-on-year, realized net profit of 240 million yuan, +13.4% year-on-year, and realized net profit of 240 million yuan after deduction of non-return to mother, year-on-year +
Review of the 2023 annual performance report of Sinqi Pharmaceutical (300573): The annual report results are in line with expectations, and the performance of large single products is expected to explode
Incident: On April 18, 2024, the company issued an announcement. In 2023, it achieved operating income of 1,468 billion yuan, an increase of 17.42% over the previous year; achieved net profit of 240 million yuan, an increase of 13.39% over the previous year
SDIC Securities released a research report on April 19 stating that it gave Sinqi Pharmaceutical (300573.SZ) a purchase rating, and the target price was 241.50 yuan. The main reasons for the rating include: 1) continued release of core products to help th
SDIC Securities released a research report on April 19 stating that it gave Sinqi Pharmaceutical (300573.SZ) a purchase rating, and the target price was 241.50 yuan. The main reasons for the rating include: 1) continued release of core products to help the company's performance grow steadily; 2) sales of key varieties of ciclosporin eye drops continued to grow at a high rate after being included in medical insurance. (Mainichi Keizai Shimbun)
Express News | Insurance capital appeared among the top ten tradable shareholders with 32 individual shares
Express News | Sinqi Pharmaceutical: Net profit of 240 million yuan in 2023 increased 13.39% year-on-year, and plans to increase 10 to 4 distributions of 30 yuan
No Data